Track Enovis Corporation Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Enovis Corporation Common Stock ENOV · Stock Open Enovis Corporation Common Stock in new tab

27.68 USD
EPS
-9.23
P/B
1.10
ROE
-29.95
Beta
1.42
Target Price
37.83 USD
Enovis Corporation Common Stock logo

Enovis Corporation Common Stock

🧾 Earnings Recap – Q2 2025

Enovis reported solid second-quarter performance, achieving 7% revenue growth and a strong shift towards improved margins under new CEO Damien McDonald’s leadership.

  • Revenue increased to $2.2 billion, up from $1.4 billion since the spin-off, supported by successful acquisitions and organic growth.
  • Adjusted EBITDA margins improved from 14% to nearly 18%, reflecting operational enhancements and disciplined capital allocation strategies.
  • Strong demand and effective cash management led to positive cash flow, amid challenges from tariffs.
  • The company is prioritizing commercial execution, innovation, and operational excellence to drive future growth and enhance patient outcomes.
  • Continued focus on embedding financial discipline across the organization to reduce costs and improve working capital efficiency.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
EPS-9.23
Book Value25.88
Price to Book1.10
Debt/Equity89.77
% Insiders1.644%
Growth
Revenue Growth0.02%
Estimates
Forward P/E8.14
Forward EPS3.51
Target Mean Price37.83

DCF valuation

Model fair value for Enovis Corporation Common Stock (ENOV)
Result
Sign in to run the valuation for ENOV.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
12 analysts · consensus Strong buy · mean target 37.83 USD (low 27.00, high 47.00) · as of 12 Nov 2026
Low 27.00
Mean 37.83
High 47.00
Price 27.68
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Enovis Corporation Common Stock Logo Enovis Corporation Common Stock Analysis (ENOV)

United States Industrials Official Website Stock

Is Enovis Corporation Common Stock a good investment? Enovis Corporation Common Stock (ENOV) is currently trading at 27.68 USD. Market analysts have a consensus price target of 37.83 USD. This suggests a potential upside from current levels.

Earnings Schedule: Enovis Corporation Common Stock is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is 3.51.

Investor FAQ

Does Enovis Corporation Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Enovis Corporation Common Stock?

Enovis Corporation Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -9.23.

Company Profile

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.

Exchange Ticker
ASE (United States) ENOV
LSE (United Kingdom) 0I1B.L
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 5, 2022 0.58
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion